RECRUITINGOBSERVATIONAL
LUPKYNIS Drug-use Results Survey
About This Trial
The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients who are newly starting administration of LUPKYNIS for lupus nephritis
Who Should NOT Join This Trial:
\-
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients who are newly starting administration of LUPKYNIS for lupus nephritis
Exclusion Criteria:
\-
Treatments Being Tested
DRUG
Voclosporin (LUPKYNIS)
In general, for adults, voclosporin should be administered orally at a dose of 23.7 mg BID. The dosage may be appropriately reduced depending on the patient's condition. In principle, at the start of treatment with voclosporin, it should be used in combination with corticosteroids and mycophenolate mofetil.
Locations (1)
Pharmacovigilance Department
Osaka, Osaka, Japan